John Renger - 09 Feb 2022 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Role: Chief Scientific Officer
Signature: /s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 09 Feb 2022
Net transactions value: -$662,500
Form type: 4
Filing time: 11 Feb 2022, 17:46:43 UTC
Previous filing: 28 Dec 2021
Next filing: 04 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CERE	Common Stock	Options Exercise	$87,500	+25,000	+1263%	$3.50^*	26,980	09 Feb 2022	Direct	F1
transaction	CERE	Common Stock	Sale	$750,000	-25,000	-93%	$30.00	1,980	09 Feb 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CERE	Stock Option (Right to Buy)	Options Exercise	$0	-25,000	-6.7%	$0.000000	345,875	09 Feb 2022	Common Stock	25,000	$3.50	Direct	F1, F2
transaction	CERE	Stock Option (Right to Buy)	Award	$0	+168,856		$0.000000	168,856	09 Feb 2022	Common Stock	168,856	$30.36	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These transactions were effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2021 adopted by the Reporting Person.
F2	25% of the shares subject to this option vested and became exercisable on April 8, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.
F3	25% of this option shall vest and become exercisable on February 9, 2023, with the remainder vesting in thirty-six (36) monthly installments thereafter.